# Peptide therapy in the news.

> Source: https://peptidewellnessusa.com/news/
> The Daily · 11 articles live
> Every page of this site in Markdown: https://peptidewellnessusa.com/llms.txt

What changed this week, this month — regulation, research, industry. Reported with primary sources, not press-release copy. New entries appear here as they ship.

## Lifting weights on tirzepatide: the first randomised trial

- [Lifting weights on tirzepatide: the first randomised trial](https://peptidewellnessusa.com/news/tirzepatide-resistance-training-rct-november-2026/)
- [ResearchNov 4, 2026 Retatrutide beat Ozempic 2 mg in its first head-to-head trial 3 min read R](https://peptidewellnessusa.com/news/retatrutide-vs-ozempic-transcend-t2d-2-october-2026/)
- [IndustryNov 2, 2026 LegitScript will now certify sellers of six compounded peptides 2 min read I](https://peptidewellnessusa.com/news/legitscript-peptide-certification-november-2026/)
- [RegulatoryOct 28, 2026 HHS lets pharmacies compound six peptides, with conditions 6 min read R](https://peptidewellnessusa.com/news/hhs-peptide-compounding-enforcement-policy-october-2026/)

## By rubric.

- [SafetyOct 21, 2026 Two compounders recall GLP-1 injections over sterility The FDA's October 14 Enforcement Report lists 18 recalled compounded injections from two pharmacies, ten of them tirzepatide or semaglutide. Both firms had received FDA warning letters before. Here is what was recalled, what the recall class means, and what to check if you have a vial or syringe at home. 3 min read](https://peptidewellnessusa.com/news/compounded-glp-1-sterility-recalls-october-2026/)
- [PricesSep 11, 2026 GLP-1 prices barely moved in 2026. Here is the data We recorded what nine GLP-1 sellers charged from January to August: from archived copies of their pages until late June, then every day. One of them actually changed its price. Three other movements our ledger recorded were us correcting what we had been counting as a price. 6 min read](https://peptidewellnessusa.com/news/glp-1-price-history-january-august-2026/)
- [IndustryAug 18, 2026 GLP-1 muscle loss: what Nestle's new push reveals Nestle says it is building products for people on Ozempic and Wegovy, starting with the muscle they lose. The loss is real and well measured — but only one intervention reliably reduces it. 8 min read](https://peptidewellnessusa.com/news/glp-1-muscle-loss-nestle-august-2026/)
- [RegulatoryJul 28, 2026 FDA warning letters now reach research-peptide sellers Eleven sellers of "research use only" peptides have been cited since March. The run was a GLP-1 story until June, when one letter named Prostamax and gonadorelin. On 24 August the agency sent five more at once, and every one of them names PT-141 and tesamorelin alongside the GLP-1s. FDA reviewed all five websites in July — the month its own advisers voted to recommend six peptides for legal compounding. 10 min read](https://peptidewellnessusa.com/news/fda-warning-letters-research-peptide-sellers-2026/)
- [RegulatoryJul 27, 2026 FDA advisory panel overruled its reviewers on six of seven FDA's own scientists proposed no on all seven peptides. Its advisory committee voted yes on six — BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax — and rejected only Emideltide. The full vote record, from FDA's own broadcast, and what it changes. 8 min read](https://peptidewellnessusa.com/news/pcac-peptide-vote-results-july-2026/)
- [RegulatoryJul 22, 2026 FDA reviewers say no: seven peptides face 503A advisory vote Our pre-meeting preview of the July 23–24 PCAC review of seven peptides for the 503A bulks list, setting out FDA's position going in: for every one of them, the agency's proposed answer was the same. Do not add it. The committee has since voted the other way on six of the seven. 6 min read](https://peptidewellnessusa.com/news/pcac-503a-bulks-list-peptides-july-2026/)
- [RegulatoryJun 18, 2026 FDA cited 25 telehealth GLP-1 sellers in one wave The agency posted a batch of warning letters on June 16 — 25 of them aimed at compounded semaglutide and tirzepatide marketing. We pulled five of the letters and grouped what FDA actually objected to, who got named, and how it lines up with the parallel rulemaking, whose comment period was later extended to July 30. 6 min read](https://peptidewellnessusa.com/news/fda-warning-letters-compounded-glp-1-june-2026/)